|Last Price$89.84||Day Change (%)0.12%|
|Open Price$89.79||Day Change ($)0.11|
|Day Range89.51–89.99||52-Week Range72.24–91.66|
As of Fri 08/29/2014 04:31 PM EST | USD
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
Ipsen: 2014 Half-Year Results and 2014 Objectives
As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.
Recent deals have been driven more by tax strategies than therapeutic synergies.
On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...
Novartis NVS announced Friday that it is removing Zelnorm for irritable bowel syndrome from the U.S. market at the request of the Food and Drug Administration. We think Zelnorm could eventually return to pharmacy shelves in the United States, but we have drastically reduced our estimate of sales ...
Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company
Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition